Preview

Rational Pharmacotherapy in Cardiology

Advanced search

UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE

https://doi.org/10.20996/1819-6446-2012-8-2-26-30

Full Text:

Abstract

Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + clopidogrel) use in patients having appropriate indications according to current clinical guidelines and to study the possibility of prescription rate improvement by education activity directed to doctors. Material and methods. The study consisted of 3 parts. Parts I and II present the results of two questionnaire surveys of patients with acute myocardial infarction, or stenting, who needed in DAT according to current clinical guidelines. The real use of the DAT was assessed in part III on the basis of the multicenter study conducted in different regions of Russia (ROMB study) in a large sample of patients having DAT indications. Results. Part I - PROGNOZ-IBS study. According to the questionnaire survey only 112 out of 239 patients (47%) having an absolute indications, received DOT. Part II - phone survey of patients with acute myocardial infarction in two towns of Lyubertsy and Podolsk. 28 of 71 patients (39%) took the DAT (from some days to 6 months) and 35 patients (49%) — did not take it. Part III - ROMB study. 519 patients did not take DAT, at that 259 (50%) in hospital and 260 (50%) - in out-patient clinic. 521 patients took DAT according to indications, at that 238 (46%) in hospital and 283 (54%) - in out-patient clinic. Conclusion. Less than 50% of patients, having direct indications, received DAT in the real clinical practice. The prescription rate can be improved due to education activity directed to doctors and increase in clopidogrel drugs affordability.

About the Authors

S. Yu. Martsevich
State Research Center for Preventive Medicine I.M. Setchenov First Moscow State Medical University
Russian Federation


V. P. Voronina
State Research Center for Preventive Medicine
Russian Federation


M. L. Ginzburg
State Research Center for Preventive Medicine Lyubertsy Regional Hospital №2
Russian Federation


N. P. Kutishenko
State Research Center for Preventive Medicine I.M. Setchenov First Moscow State Medical University
Russian Federation


Yu. N. Polyanskaya
State Research Center for Preventive Medicine
Russian Federation


T. G. Kheliya
State Research Center for Preventive Medicine
Russian Federation


A. M. Malysheva
State Research Center for Preventive Medicine
Russian Federation


S. N. Tolpygina
State Research Center for Preventive Medicine
Russian Federation


V. S. Kutuzova
Podolsky City Hospital
Russian Federation


E. A. Gofman
State Research Center for Preventive Medicine
Russian Federation


A. D. Deev
State Research Center for Preventive Medicine
Russian Federation


References

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 2002; 324: 71–86.

2. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Col- laborative Group. Lancet 1988; 2 (8607): 349–360.

3. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006; 27: 1341–1381.

4. King SB 3rd, Smith SC Jr , Hirshfeld JW Jr , et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guide-line Update for Percutaneous Coronary Intervention. J Am Coll Cardiol 2008;51;172–209.

5. Expert Consensus Document on the use of antiplatelet agents. The Task Force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004; 25:166–81.

6. The efficacy and safety of drug therapy for primary and secondary prevention of cardiovascular disease. Recommendations of the Russian Scientific Society of Cardiology (2011). Rational Pharmacother Card 2011; 7 (5) suppl: 36–42. Russian (Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. Рекомендации ВНОК (2011). РФК 2011; 7 (5) приложение: 36–42).

7. Chen ZM, Jiang LX, Chen YP , et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366 (9497): 1607–1621.

8. CAPRIE Steering Committee a randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348: 1329–1339.

9. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336 (7637); 195–198.

10. Holmes DR, Jr ., Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardio- vascular Angiography and interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010; 56 (4): 321–341.

11. Martsevich S.Yu., Ginzburg M.L., Malysheva A.M., et al. Current antiplatelet therapy in patients with ischemic heart disease with a high risk of thrombotic complications. These evidence-based medicine and actual practice. Rational Pharmacother Card 2011;7(3): 319–322. Russian (Марцевич С.Ю., Гинзбург М.Л., Малышева А.М., и др. Современная терапия антиагрегантами больных ишемической болезнью сердца с высоким риском тромботических осложнений. Данные доказательной медицины и реальная практика. РФК 2011;7(3): 319–322).

12. Martsevich S.Yu., Kutishenko N.P ., Ginzburg M.L., et al. Antiplatelet therapy in patients at high risk of thrombotic complications: the problem of efficiency , safety and commitment. Klinitsist 2011;2: 72–

13. Russian (Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л., и др. Антиагрегантная терапия у больных с высоким риском развития тромботических осложнений: проблема эффективности, безопасности и приверженности. Клиницист 2011;2: 72–79).

14. Yakusevich V.V., Petrochenko A.S., Simonov V.A., et al. Therapeutic equivalence of the original clopidogrel (Plavix) and of generic copies (Egitromb). The results of a comparative randomized blind crossover study. Rational Pharmacother Card 2011;7(1): 19–25. Russian (Якусевич В.В., Петроченко А.С., Симонов В.А., и др. Терапевтическая эквивалентность оригинального клопидогрела (Плавикс) и его дженерической копии (Эгитромб). Результаты сравнительного рандомизированного перекрестного слепого исследования. РФК 2011;7(1): 19–25).


For citation:


Martsevich S.Yu., Voronina V.P., Ginzburg M.L., Kutishenko N.P., Polyanskaya Yu.N., Kheliya T.G., Malysheva A.M., Tolpygina S.N., Kutuzova V.S., Gofman E.A., Deev A.D. UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2012;8(2):163-167. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-2-26-30

Views: 382


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)